# 2025, Publikationserhebung, Allgemeine Pathologie Heidelberg

*Rot: Erst/Letztautorenschaft*
*geteilte Erst- oder Letztautorenschaft

## PEER- REVIEWED PUBLICATIONS

1. Abooali M, Schlichtner S, Lei X, Aliu N, Ruggiero S, Loges S, Ziegler M, Hertel F**, Volckmar AL**, **Stenzinger A**, Christopoulos P, Thomas M, Klenova E, Meyer NH, Boussios S, Heaton N, Zen Y, Zamalloa A, Chokshi S, Urbani L, Richard S, Kirubendran K, Hussain R, Siligardi G, Cholewa D, Berger SM, Yasinska IM, Fasler-Kan E, Sumbayev VV. Intracellular and extracellular activities of V-domain Ig-containing suppressor of T cell activation (VISTA) modulated by immunosuppressive factors of tumour microenvironment. Cancer Lett. 2025 Apr 28;616:217581. (IF 10.1)
2. **Albrecht T, Rossberg A, Rose F, Breuhahn K, Baumann EM, Tóth M, Brinkmann F, Charbel A,** Vogel MN, Köhler B, Mehrabi A, Büchler MW, Singer S, Solass W, Straub B, **Schirmacher P**, **Roessler S, Goeppert B.** Combined analysis of albumin in situ hybridisation and C reactive protein immunohistochemistry for the diagnosis of intrahepatic cholangiocarcinoma: towards a molecular classification paradigm. J Clin Pathol. 2025 Apr 17;78(5):307-316. (IF 2.0)
3. Altmayer NC, Khajeh E, Fellhofer-Hofer J, Lintner A, Fink MA, **Schwab C**, Halama N, Nickel F, Mehrabi A, Klupp F. Interdisciplinary evidence-based tumor board simulation training in surgical medical education. Langenbecks Arch Surg. 2025 Sep 5;410(1):267. (IF 1.8) 3057
4. Angwin C, Byers P, Dulfer E, Ghali N, Harris J, **Hausser I**, McElroy A, Sobey G, van Dijk FS. The Natural History of Dermatosparaxis Ehlers Danlos Syndrome: An Adult Case Series. Am J Med Genet A. 2025 Apr;197(4):e63957. (IF 1.7)
5. **Ball M, Romanovsky E, Schnecko F, Kirchner M, Neumann O, Brandt R, Beck S, Seker-Cin H, Kluck K, Ourailidis I, Goldschmid H, Fink A, Volckmar AL, Menzel M, Allgäuer M, Schirmacher P, Budczies J, Stenzinger A, Kazdal D**. Clinical Implementation of a High-Throughput Automated Comprehensive Genomic Profiling Test: TruSight Oncology 500 HT. J Mol Diagn. 2025 Feb;27(2):154-162. (IF 3.4)
6. Ben Khaled N, Zarka V, Hobeika B, Schneider J, Rau M, Weich A, Leicht HB, Ye L, Piseddu I, Dill MT, Kandulski A, Pinter M, Ehmer U, **Schirmacher P,** Marquardt JU, Mayerle J, De Toni EN, Geier A, Reiter FP. Therapeutic Sequences of Systemic Therapy After Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma: Real-World Analysis of the IMMUreal Cohort. Aliment Pharmacol Ther. 2025 Jun;61(11):1755-1766. (IF 6.7)
7. Bitzer M, Groß S, Albert J, Blödt S, Boda-Heggemann J, Borucki K, Brunner T, Caspari R, Dombrowski F, Evert M, Follmann M, Freudenberger P, Gani C, Gebert J, Geier A, Gkika E, Götz M, Helmberger T, Hoffmann RT, Huppert P, Krug D, Fougère C, Lang H, Langer T, Lenz P, Lüdde T, Mahnken A, Nadalin S, Nguyen HHP, Nothacker M, Ockenga J, Oldhafer K, Ott J, Paprottka P, Pereira P, Persigehl T, Plentz R, Pohl J, Recken H, Reimer P, Riemer J, Ringe K, Roeb E, Rüssel J, Schellhaas B, **Schirmacher P**, Schlitt HJ, Schmid I, Schütte K, Schuler A, Seehofer D, Sinn M, Stengel A, Steubesand N, Stoll C, Tannapfel A, Taubert A, Trojan J, van Thiel I, Utzig M, Vogel A, Vogl T, Wacker F, Waidmann O, Wedemeyer H, Wege H, Wenzel G,

Wildner D, Wörns MA, Galle P, Malek N. S3-Leitlinie Diagnostik und Therapie des Hepatozellulären Karzinoms – Kurzversion. Z Gastroenterol. 2025 Mar;63(3):293-336. German. ( IF 1.6)

8. Bitzer M, Groß S, Albert J, Blödt S, Boda-Heggemann J, Borucki K, Brunner T, Caspari R, Dombrowski F, Evert M, Follmann M, Freudenberger P, Gani C, Gebert J, Geier A, Gkika E, Götz M, Helmberger T, Hoffmann RT, Huppert P, Krug D, La Fougère C, Lang H, Langer T, Lenz P, Lüdde T, Mahnken A, Nadalin S, Nguyen HHP, Nothacker M, Ockenga J, Oldhafer K, Ott J, Paprottka P, Pereira P, Persigehl T, Plentz R, Pohl J, Recken H, Reimer P, Riemer J, Ringe K, Roeb E, Rüssel J, Schellhaas B, **Schirmacher P,** Schlitt HJ, Schmid I, Schütte K, Schuler A, Seehofer D, Sinn M, Stengel A, Steubesand N, Stoll C, Tannapfel A, Taubert A, Trojan J, van Thiel I, Utzig M, Vogel A, Vogl T, Wacker F, Waidmann O, Wedemeyer H, Wege H, Wenzel G, Wildner D, Wörns MA, Galle P, Malek N. S3-Leitlinie Diagnostik und Therapie des Hepatozellulären Karzinoms – Langversion. Z Gastroenterol. 2025 Mar;63(3):e159-e260. German. (IF 1.6)
9. Blandino A, Scherer D, Boekstegers F, Rounge TB, Langseth H, **Roessler S**, Hveem K, Brenner H, Pechlivanis S, Waldenberger M, Lorenzo Bermejo J. Small-RNA sequencing reveals potential serum biomarkers for gallbladder cancer: Results from a three-stage collaborative study of large European prospective cohorts. Eur J Cancer. 2025 Jan;214: 115138. (IF 7.1)
10. Bozorgmehr F, Chung I, Fischer JR, Bischof M, Atmaca A, Wetzel S, Faehling M, Bottke D, Wermke M, Troost EGC, Kropf-Sanchen C, Wiegel T, Schmidt B, Stupavsky A, Engel-Riedel W, Hammer-Hellmig M, Reinmuth N, Manapov F, Grohe C, Krempien R, Schumann C, Sterzing F, Reck M, Würschmidt F, Fleckenstein J, Petroff A, Henschke S, Behnisch R, Cvetkovic J, Brückner L, **Schwab C, Stenzinger A,** Götze T, Kopp C, Schröder H, Debus J, Christopoulos P, Thomas M, Rieken S. Reconsidering palliative radiotherapy in addition to PD-1 blockade for non-small cell lung cancer: results from the FORCE phase II trial (AIO/YMO-TRK-0415). Clin Exp Metastasis. 2025 Jul 24;42(5):42. (IF 3.2)
11. Breunis W*, Brack E*, Ehlers AC, Bechtold I, Kisele S, Wurth J, Mous L, Zabele D, Steffen F, Zahnow F, Britschgi C, Bankel L, Rothermundt C, Vetter C, Müller D, Botter S, Pauli C, Bode P, Rinner B, Bourquin JP, Roessler J, **Grünewald TGP**, Schäfer BW, Surdez D, Wachtel M. Patient-derived tumoroids from CIC::DUX4 rearranged sarcoma identify MCL1 as a therapeutic target. Nat Commun. 2025 Aug 21;16(1):7688. (IF 15.7)
12. Burt AD, Gouw ASH, Callea F, Clouston AD, Dienes HP, Goodman ZD, Kakar S, Kleiner DE, Lackner C, Park YN, Roberts EA, **Schirmacher P,** Terracciano L, Tiniakos D, Torbenson M, Wanless IR, Weber A, Zen Y. Making Sense of 'Porto-Sinusoidal Vascular Disorder': What Does It Mean for the Pathologist and the Patient? Liver Int. 2025 Jan;45(1): e16196. (IF 5.2)
13. Castoldi M, Roy S, Angendohr C, **Pellegrino R**, Vucur M, Singer MT, Buettner V, Dille MA, Wolf SD, Heij LR, Ghallab A, Albrecht W, Hengstler JG, Flügen G, Knoefel WT, Bode JG, Zender L, Neumann UP, Heikenwälder M, **Longerich T**, Roderburg C, Luedde T. Regulation of KIF23 by miR-107 controls replicative tumor cell fitness in mouse and human hepatocellular carcinoma. J Hepatol. 2025 Mar;82(3):499-511. ( IF 33.0)
14. Ceranski AK, Carreño-Gonzalez MJ, Ehlers AC, Hanssen KM, Gmelin N, Geyer FH, Kolodynska Z, Vinca E, Faehling T, Poeller P, Ohmura S, Cidre-Aranaz F, Schulze A, **Grünewald TGP.** Refined culture conditions with increased physiological relevance uncover oncogene-dependent metabolic signatures in Ewing sarcoma spheroids. Cell Rep Methods. 2025 Feb 24;5(2):100966. (IF 4.5)
15. Chantreau PL, Sohier P, Samimi M, Tallegas M, Tallet A, Guyetant S, Goeppert B, Al-Hussaini M, Toberer F, Giese N, **Roessler S**, von Deimling A, Kervarrec T. Methylation profiling: a

diagnostic tool for the diagnosis of Merkel cell carcinoma of the lymph node without detectable skin primary tumor. Virchows Arch. 2025 Nov;487(5):1143-1149. (IF 3.1)

16. Cheytan T, Schneider M, Würth R, Schwerd-Kleine P, **Gutjahr E,** Thewes V, Michel LL, Weber R, Vorberg T, Lohr S, Nitschke K, Neßling M, Lichter P, Schneeweiss A, Richter K, Helm D, Sprick M, Trumpp A. Small extracellular vesicles and particles (sEVPs) derived from tumor-free pre-metastatic organs promote breast cancer metastasis and support organotropism. Mol Cancer. 2025 Mar 8;24(1):72. (IF 33.9)
17. Chicón-Bosch M, Sánchez-Serra S, Rosàs-Lapeña M, Costa-Fraga N, Besalú-Velázquez J, Illa-Bernadí J, Mateo-Lozano S, Cidre-Aranaz F, **Grünewald TGP**, Díaz-Lagares Á, Lopez-Alemany R, Tirado ÒM. Multi-omics profiling reveals key factors involved in Ewing sarcoma metastasis. Mol Oncol. 2025 Apr;19(4):1002-1028. (IF 4.5)
18. Cidre-Aranaz F*, Magrin C*, Zimmermann M, Li J, Baffa A, Ciccaldo M, Hartmann W, Dirksen U, Sola M, Paganetti P*, **Grünewald TGP***, Papin S*. High Tau expression correlates with reduced invasion and prolonged survival in Ewing sarcoma. Cell Death Discov. 2025 May 3;11(1):216. (IF 7.0)
19. Cinnamon E, Stein I, Zino E, Rabinovich S, Shovman Y, Schlesinger Y, Salame TM, Reich-Zeliger S, **Albrecht T, Roessler S, Schirmacher P,** Lotem M, Ben-Neriah Y, Parnas O, Pikarsky E. RORc-expressing immune cells negatively regulate tertiary lymphoid structure formation and support their pro-tumorigenic functions. J Hepatol. 2025 Jun;82(6):1050-1067. (IF 33.0)
20. Crnovrsanin N, Zumsande S, Rompen IF, Schiefer S, Zimmer S, Hu W, **Arnscheidt J, Brinkmann F, Longerich T,** Haag GM, Schmidt T, Al-Saeedi M, Sisic L, Nienhüser H. β-Blockers Influence Oncological Outcomes in Gastric Cancer Patients Treated with Neoadjuvant Chemotherapy Based on the Pathological Subtype: A Retrospective Cohort Study. Ann Surg Oncol. 2025 Jul;32(7):5142-5153. (IF 3.5)
21. Damerell V, Klaassen-Dekker N, Brezina S, Ose J, Ulvik A, van Roekel EH, Holowatyj AN, Baierl A, Böhm J, Bours MJL, Brenner H, de Wilt JHW, Grady WM, Habermann N, Hoffmeister M, Keski-Rahkonen P, Lin T, **Schirmacher P**, Schrotz-King P, Ulrich AB, van Duijnhoven FJB, Warby CA, Shibata D, Toriola AT, Figueiredo JC, Siegel EM, Li CI, Gsur A, Kampman E, Schneider M, Ueland PM, Weijenberg MP, Ulrich CM, Kok DE, Gigic B; FOCUS Consortium. Circulating tryptophan-kynurenine pathway metabolites are associated with all-cause mortality among patients with stage I-III colorectal cancer. Int J Cancer. 2025 Feb 1;156(3):552-565. (IF 4.7)
22. Eichhorn ME, Niedermaier B, Charoentong P, Klotz LV, Baum P, Griffo R, **Allgäuer M**, **Stenzinger A**, Bischoff H, Schneider MA, Christopoulos P, Haberkorn U, Heußel CP, Savai R, Roberti MP, Zoernig I, Jäger D, Herth F, Thomas M, Winter H, Eichhorn F. Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: results of the NEOMUN trial. J Immunother Cancer. 2025 Aug 4;13(8):e011874. (IF 10.6)
23. Eickelschulte S, Kaczorowski A, Janke F, Riediger AL, Lazareva O, Böning S, Kristiansen G, **Schwab C, Stenzinger A**, Sültmann H, Duensing S, Duensing A, Görtz M. Digital spatial profiling identifies phospho-JNK as a biomarker for early risk stratification of aggressive prostate cancer. Front Oncol. 2025 Jun 5;15:1572299. (IF 3.3)
24. Eloy C, Fraggetta F, van Diest PJ, Polónia A, Curado M, Temprana-Salvador J, Zlobec I, Purqueras E, **Weis CA**, Matias-Guiu X, **Schirmacher P**, Ryška A. Digital transformation of pathology - the European Society of Pathology expert opinion paper. Virchows Arch. 2025 Nov;487(5):971-981. (IF 3.1)
25. Eswaran S, Gebert L, Schraven S, Treichel N, **Ritz T,** Hamm S, Seeger A, Kiessling F, Clavel T, Dreschers S, Wagner N, Schippers A. Intercellular adhesion molecule-1 protects against

adipose tissue inflammation and insulin resistance but promotes liver disease activity in western-diet fed mice. Sci Rep. 2025 Jul 17;15(1):25884. (IF 3.9)

26. Fichtner A, Gauché L, Süsal C, Tran TH, **Waldherr R**, Krupka K, Guzzo I, Carraro A, Oh J, Zirngibl M, Weitz M, König J, Büscher A, Berta L, Simon T, Awan A, Rusai K, Topaloglu R, Peruzzi L, Printza N, Kim JJ, Weber LT, Melk A, Pape L, Rieger S, Patry C, Höcker B, Tönshoff B; CERTAIN study group. Incidence, risk factors, management strategies, and outcomes of antibody-mediated rejection in pediatric kidney transplant recipients-a multicenter analysis of the Cooperative European Paediatric Renal Transplant Initiative (CERTAIN). Pediatr Nephrol. 2025 Feb;40(2):491-503. (IF 2.6)
27. Filippidou M, Glentis S, Rigatou E, Sievers P, Selt F, Dimitriadis E, Perari P, Binenbaum I, Avgerinou G, van Tilburg CM, Jones DTW, Sahm F, Milde T, Witt O, Pfister SM, **Grünewald TGP**, Stefanaki K, Kattamis A. Soft Tissue Undifferentiated Sarcoma Carrying a Novel Onecut1::Nutm1 Fusion. Pediatr Blood Cancer. 2025 Jan;72(1): e31427. (IF 2.3)
28. Funk CM*, Ehlers AC*, Orth MF, Aljakouch K, Li J, Hölting TL, Will R, Geyer FH, Ceranski AK, Willis F, Vinca E, Ohmura S, Imle R, Siebenlist J, Yershova A, Knott MM, Zahnow F, Sastre A, Alonso J, Sahm F, Peterziel H, Loboda A, Schneider M, Banito A, Leprivier G, Hartmann W, Dirksen U, Witt O, Oehme I, Pfister SM, Romero-Pérez L, Krijgsveld J, Cidre-Aranaz F**, Grünewald TG***, Musa J*. High 4E-BP1 expression associates with chromosome 8 gain and CDK4/6 sensitivity in Ewing sarcoma. J Clin Invest. 2025 Oct 16;135(24):e187627. (IF 13.6)
29. Galvan B, Ongena L, Bruyr J, Fettweis G, Lucarelli E, Lavergne A, Mariavelle E, O'Grady TM, Hassoun ZEO, Claes M, Dubois L, Lee KAW, Kruys V, Gueydan C, Durand J, Hervouet E, Geyer FH, Banito A, Imle R, Mao L, Jayavelu AK, **Grünewald TGP**, Cidre-Aranaz F, Twizere JC, Dequiedt F. Subversion of mRNA degradation pathways by EWSR1::FLI1 represents a therapeutic vulnerability in Ewing sarcoma. Nat Commun. 2025 Jul 16;16(1):6537. (IF 15.7)
30. Garcia-Foncillas J, Bayle A, Arnold D, Avouac B, Awada A, de la Cruz-Merino L, Helland Å, Lassen U, Laurent-Puig P, Normanno N, Rohrberg K, Taieb J, **Stenzinger A.** Overcoming barriers to advanced biomolecular technologies that inform treatment of solid tumors: a roadmap to access. Future Oncol. 2025 Jun;21(14):1745-1752. (IF 2.6)
31. Gehrs S, Jakab M, **Gutjahr E**, Gu Z, Weichenhan D, Mallm JP, Mogler C, Schlesner M, Plass C, Schlereth K, Augustin HG. The spatial zonation of the murine placental vasculature is specified by epigenetic mechanisms. Dev Cell. 2025 May 19;60(10):1467-1482.e8. (IF 8.7)
32. Geyer FH, Ritter A, Kinn-Gurzo S, Faehling T, Li J, Jarosch A, Ngo C, Vinca E, Aljakouch K, Orynbek A, Ohmura S, Kirchner T, Imle R, Romero-Pérez L, Díaz-Martín J, Bertram S, de Álava E, Henon C, Postel-Vilnay S, Banito A, Sill M, Versleijen-Jonkers Y, Mayer BFB, Ebinger M, Sparber-Sauer M, Stegmaier S, Baumhoer D, Hartmann W, Krijgsveld J, Horst D, Delattre O, Grohar PJ, **Grünewald TGP**, Cidre-Aranaz F. Comprehensive DSRCT multi-omics analyses unveil CACNA2D2 as a diagnostic hallmark and super-enhancer-driven EWSR1::WT1 signature gene. Cancer Commun (Lond). 2025 Jun;45(6):702-708. (IF 24.9)
33. Glemser PA, Netzer N, Ziener CH, Wilhelm M, Hielscher T, Zhang KS, Görtz M, Schütz V, **Stenzinger A**, Hohenfellner M, Schlemmer HP, Bonekamp D. Improving risk stratification of PI-RADS 3 + 1 lesions of the peripheral zone: expert lexicon of terms, multi-reader performance and contribution of artificial intelligence. Cancer Imaging. 2025 Aug 19;25(1):102. (IF 3.5)
34. Glenny EM, Lin T, Bandera VM, Mirminachi B, Khumukcham SS, Gigic B, Warby CA, Aksonova O, Coleman MF, Carpanese A, Busch C, Himbert C, Ose J, Nix DA, Boucher K, **Schirmacher P,** Strehli I, Hardikar S, Cohan JN, Jedrzkiewicz J, **Brobeil A**, Schneider MA, Kahlert C, Siegel EM, Byrd DA, Toriola AT, Shibata D, Li CI, Figueiredo JC, Tan AC, Roper J, Ulrich CM, Hursting SD. Obesity promotes conserved inflammatory and metabolic transcriptional programs in colon

tumors: evidence from mouse models and the ColoCare Study Patient Cohort. Am J Clin Nutr. 2025 Dec;122(6):1545-1556. (IF 6.9)

35. **Goeppert B, Charbel A**, Toth R, Zhang Y, Tabbakh D, **Albrecht T**, Schrimpf D, de Mestier L, Cros J, Vogel MN, Chang DH, **Bohn EM, Brobeil A**, Ji J, Singer S, Nazarov PV, Perren A, Apostolidis L, von Deimling A, **Roessler S**. DNA methylation patterns facilitate tracing the origin of neuroendocrine neoplasms. Nat Commun. 2025 Oct 27;16(1):9477. (IF 15.7)
36. Groß S, Bitzer M, Albert J, Blödt S, Boda-Heggemann J, Borucki K, Brunner T, Caspari R, Dombrowski F, Evert M, Follmann M, Freudenberger P, Gani C, Gebert J, Geier A, Gkika E, Götz M, Helmberger T, Hoffmann RT, Huppert P, Krug D, La Fougère C, Lang H, Langer T, Lenz P, Lüdde T, Mahnken A, Nadalin S, Nguyen HHP, Nothacker M, Ockenga J, Oldhafer K, Ott J, Paprottka P, Pereira P, Persigehl T, Plentz R, Pohl J, Recken H, Reimer P, Riemer J, Ringe K, Roeb E, Rüssel J, Schellhaas B, **Schirmacher P**, Schlitt HJ, Schmid I, Schütte K, Schuler A, Seehofer D, Sinn M, Stengel A, Steubesand N, Stoll C, Tannapfel A, Taubert A, Trojan J, van Thiel I, Utzig M, Vogel A, Vogl T, Wacker F, Waidmann O, Wedemeyer H, Wege H, Wenzel G, Wildner D, Wörns MA, Galle P, Malek N. S3-Leitlinie Diagnostik und Therapie biliärer Karzinome – Kurzversion. Z Gastroenterol. 2025 Feb;63(2):169-203. German. ( IF 1.6)
37. Groß S, Bitzer M, Albert J, Blödt S, Boda-Heggemann J, Borucki K, Brunner T, Caspari R, Dombrowski F, Evert M, Follmann M, Freudenberger P, Gani C, Gebert J, Geier A, Gkika E, Götz M, Helmberger T, Hoffmann RT, Huppert P, Krug D, Fougère C, Lang H, Langer T, Lenz P, Lüdde T, Mahnken A, Nadalin S, Nguyen HHP, Nothacker M, Ockenga J, Oldhafer K, Ott J, Paprottka P, Pereira P, Persigehl T, Plentz R, Pohl J, Recken H, Reimer P, Riemer J, Ringe K, Roeb E, Rüssel J, Schellhaas B, **Schirmacher P**, Schlitt HJ, Schmid I, Schütte K, Schuler A, Seehofer D, Sinn M, Stengel A, Steubesand N, Stoll C, Tannapfel A, Taubert A, Trojan J, van Thiel I, Utzig M, Vogel A, Vogl T, Wacker F, Waidmann O, Wedemeyer H, Wege H, Wenzel G, Wildner D, Wörns MA, Galle P, Malek N. S3-Leitlinie Diagnostik und Therapie biliärer Karzinome – Langversion. Z Gastroenterol. 2025 Feb;63(2):e82-e158. German. (IF 1.6)
38. Grossetete S, Zaidi S, Orth MF, Morice S, Laud K, Louis-Brennetot C, Ferre AS, Perrin V, Cidre-Aranaz F, Raynal V, Aynaud MM, Baulande S, Wachtel M, Janoueix-Lerosey I, Brunet E, **Grünewald TGP**, Delattre O, Surdez D. The hegemonic EWSR1 :: ETS oncoprotein overrules core regulatory circuitry principles in Ewing sarcoma. NPJ Precis Oncol. 2025 Dec 25;10(1):36. (IF 8.0)
39. Heijboer FWJ, Brambilla M, Occhipinti M, Lorenzini D, Buikhuisen WA, Kodach LL, Christopoulos P**, Stenzinger A**, Hillen LM, Garrido P, Lage Y, Benito A, Lindsay CR, Carter M, Herder J, Britstra R, van der Drift MA, de Jong WK, Schutgens FWG, Damhuis RAM, Speel EM, von der Thüsen JH, Dingemans AC, Derks JL. Actionable Genomic Alterations in Large Cell Neuroendocrine Carcinoma: A European Case Series of Patients Treated With a Small Molecule Inhibitor. JCO Precis Oncol. 2025 Nov;9: e2500293. (IF 5.8)
40. Herter S, Emperador M, Smyrilli K, Kocher D, Celikyürekli S, Zeiser C, Gerloff X, Kreth S, Henrich KO, Maaß KK, Rettenmeier J, **Grünewald TGP**, Peterziel H, Westermann F, Hamacher-Brady A, Witt O, Oehme I. High content-imaging drug synergy screening identifies specific senescence-related vulnerabilities of mesenchymal neuroblastomas. Cell Death Dis. 2025 Aug 25;16(1):644. (IF 9.6)
41. Hodge JC, Netto GJ, Rekhi B, Cooper WA, Eden M, Field AS, Goh V, Kench JG, Khoury JD, Leite KRM, Liang Z, Maeda D, Reyes-Múgica M, Rous B, Ryška A, Sayed S, Sepulveda A, Shi C, Tse G, **Schirmacher P**, Lokuhetty D. WHO Classification of Tumours: evolution of a global resource in the molecular era. Lancet Oncol. 2025 Apr;26(4):410-413. (IF 35.9)
42. Hoffmeister-Wittmann P, Hoegen-Saßmannshausen P, Wicklein L, Weykamp F, Seidensaal K, Springfeld C, Dill MT, **Longerich T, Schirmacher P**, Mehrabi A, Mathy RM, Köhler BC, Debus

J, Herfarth K, Liermann J. Stereotactic body radiotherapy with carbon ions as local ablative treatment in patients with primary liver cancer. Radiat Oncol. 2025 Feb 18;20(1):23. (IF 3.2)

43. Ibarra-Arellano MA*, Caprio LA*, Hada A, Stotzem N, Cai LL, Shah SB, Walsh ZH, Melms JC, Wünneman F, Bestak K, Mansaray I, Izar B*, **Schapiro D***. micronuclAI enables automated quantification of micronuclei for assessment of chromosomal instability. Commun Biol. 2025 Mar 4;8(1):361. (IF 5.1)
44. Imle R, Blösel D, **Kommoss FKF**, Placke S, Stutheit-Zhao E, Blume C, Lupar D, Schmitt L, Winter C, Wagner L, von Eicke M, Walzer H, Förderer J, Laier S, Hertwig M, Peterziel H, Oehme I, Scheuerman S, Seitz CM, Geyer FH, Cidre-Aranaz F, **Grünewald TGP,** Vokuhl C, Chudasama P, Scholl C, Schmidt C, Günther P, Sill M, Jones KB, Pfister SM, Autry RJ, Banito A. Somatic gene delivery faithfully recapitulates a molecular spectrum of high-risk sarcomas. Nat Commun. 2025 Jun 16;16(1):5283. (IF 15.7)
45. Janke F, Gasser M, Angeles AK, Riediger AL, Görtz M, Appenheimer L, Laut AK, Ogrodnik S, Gerhardt S, **Stenzinger A**, Schneider MA, Thomas M, Christopoulos P, Sültmann H. Low-coverage whole genome sequencing of cell-free DNA to predict and track immunotherapy response in advanced non-small cell lung cancer. J Exp Clin Cancer Res. 2025 Mar 8;44(1):87. (IF 12.8)
46. Janssen J, Andrade Barbosa B, Mocking TR, van Essen HF, Eijk PP, Egthuijsen J, Ferro A, Parracha de Matos JP, Draijer S**, Stenzinger A**, van den Berg A, Machado JC, Thunnissen E, Kim Y, Radonic T, Ylstra B. The Added Value of Genome-Wide Copy Numbers to Objectively Resolve Clonality of Multiple Tumors With Pulmonary Involvement and Ambiguous or Inconclusive Mutational Diagnosis. JTO Clin Res Rep. 2025 Oct 23;6(12):100921. (IF 3.5)
47. Ji F,* Zhang J*, Mao L*, Tan Y, Ye M, He X, Zhao Y, Liu J, Zhang Y, Zhang N, Shi J, Yan J, Cai X, Zhao B, Jin J, Xu P, **Roessler S,** Zheng X, Ji J. Liver-specific gene PGRMC1 blocks c-Myc-induced hepatocarcinogenesis through ER stress-independent PERK activation. Nat Commun. 2025 Jan 2;16(1):50. ( IF 15.7)
48. Jin JX, Fuchslocher F, Carreno-Gonzalez M, Zahnow F, Ceranski AK, Will R, Helm D, Bestvater F, Banito A, Imle R, Ohmura S, Cidre-Aranaz F, **Grünewald TGP**. Loss of SMARCB1 evokes targetable epigenetic vulnerabilities in epithelioid sarcoma. Cancer Commun (Lond). 2025 May;45(5):494-499. (IF 24.9)
49. Juan Ribelles A, Felix A, Benavent N, Escrivá-Fernández J, Brahmi M, Gaspar N, Gatz SA, **Grünewald TG**, Linder-Stragliotto C, Palmerini E, Pantziarka P, Strauss S, Surdez D, Berlanga P, McCabe MG. Recurrent and Refractory Ewing Sarcoma Phase I/II Trials: Current Perspective From the Euro-Ewing Consortium. JCO Precis Oncol. 2025 Sep;9: e2500377. (IF 5.8)
50. **Kahles A, Volckmar AL, Goldschmid H,** Salto-Tellez M, Vogeser M, Stone J, Brüggemann M, **Budczies J, Kazdal D,** Salgado R, **Schirmacher P**, Peters S, Lennerz JK, **Stenzinger A.** Regulation of laboratory-developed tests and in-house in vitro diagnostic medical devices in the United States and the European Union-a comparative overview. ESMO Open. 2025 Dec;10(12):105909. (IF 8.3)
51. Kasan M, Geyer FH, Siebenlist J, Sill M, Öllinger R, Faehling T, de Álava E, Surdez D, Dirksen U, Oehme I, Scotlandi K, Delattre O, Müller-Nurasyid M, Rad R, Strauch K, **Grünewald TGP**, Cidre-Aranaz F. Genomic and phenotypic stability of fusion-driven pediatric sarcoma cell lines. Nat Commun. 2025 Jan 3;16(1):380. (IF 15.7)
52. Kliemank E, von Rauchhaupt E, Seebauer L, Roshan M, Ansmann M, Flegka V, Schimpfle L, Tsilingiris D, Bartl H, Fleming T, Kender Z, Jende JME, Mooshage CM, Schwarz D, Bendszus M, **Schirmacher P,** Herzig S, Nawroth PP, Kopf S, Szendroedi J, Sulaj A. Cohort profile of the

Heidelberg study on diabetes and complications HEIST-DiC. Sci Rep. 2025 Aug 12;15(1):29580. (IF 3.9)

53. Klotz R*, Engerer C*, Tenckhoff S, Uzun-Lang K, **Schwab C**, Wild C, Sander A, Baumann L, Klose C, Kauczor HU, **Schirmacher P**, Jäger D, Debus J, Al-Saeedi M, Probst P, Ulrich A, Schneider M, Diener MK, Kahlert C, Michalski CW, Köhler BC, Büchler MW. Selective neoadjuvant therapy of rectal cancer patients (SELREC): study protocol for a European randomised controlled, open, multicentre non-inferiority trial. BMJ Open. 2025 Jun 26;15(6):e092807. (IF 2.3)
54. Kolodziejczak AS, Selt F, Peterziel H, Jamaladdin N, Mack N, Maaß K, Meulenbroeks C, Sigaud R, Herold-Mende C, El Damaty A, Burhenne J, Ohmura S, Holland-Letz T, Kutscher LM, Ernst A, Wei PC**, Grünewald TGP**, Oehme I, Kool M, Jones DTW, Pajtler KW, Kratz CP, Pfister SM, Witt O, Milde T. Preclinical drug screen identifies WEE1 inhibitor and vinca alkaloid as a combination treatment concept for Li-Fraumeni syndrome medulloblastoma. iScience. 2025 Dec 29;29(2):114564. (IF 4.1)
55. Koschny R, Haag GM, **Brobeil A**. A NECessary Workup: Exploring the Rare Histology of an Esophageal Tumor. United European Gastroenterol J. 2025 Oct;13(8): 1603-1604. (IF 6.7)
56. Küchler S, Brilloff S, Schäfer S, Rahimian E, Kufrin V, Peri SS, Musa J, **Grünewald TGP,** Schewe DM, Ball CR, Bornhäuser M, Glimm H, Bill M*, Wurm AA*. Cell cycle regulator MYBL2 is a distinct vulnerability in acute myeloid leukemia. Cell Death Discov. 2025 Oct 20;11(1):470. (IF 7.0)
57. Kulhavy J, Maurus K, Blasi M, Brändlein S, Reu-Hofer S, Doll J, Böck J, **Stenzinger A, Kazdal D**, **Budczies J**, Roll V, Kunzmann V, Gerhard-Hartmann E, Rosenwald A, Bargou R, Goebeler ME, Kern J, Jung P, Krebs M, Chatterjee M, Christopoulos P, Venkataramani V, Hummel HD. Impact of Baseline β-Catenin Comutations on Prognosis in EGFR-Mutant Lung Cancer. JCO Precis Oncol. 2025 Aug; 9: e2400771. (IF 5.8)
58. Lahusen A, Lutz MP, Fang R, **Kirchner M,** Albus S, **Kluck K**, Karthaus M, Schwarzer A, Siegler G, Kleger A, Ettrich TJ, Becher A, Höfling S, Siveke JT, **Budczies J**, Tannapfel A, **Stenzinger A**, Cheung PF, Eiseler T*, Seufferlein T*. An immune responsive tumor microenvironment imprints into PBMCs and predicts outcome in advanced pancreatic cancer: lessons from the PREDICT trial. Mol Cancer. 2025 Jul 22;24(1):202. (IF 33.9)
59. Lam WM, Gabernet G, **Poth T**, Sator-Schmitt M, Oquendo MB, Kast B, Lohr S, de Ponti A, Weiß L, Schneider M, Helm D, Müller-Decker K, **Schirmacher P**, Heikenwälder M, Klingmüller U, Schneller D, Geisler F, Nahnsen S, Angel P. RAGE is a key regulator of ductular reaction-mediated fibrosis during cholestasis. EMBO Rep. 2025 Feb;26(3):880-907. (IF 6.2)
60. Lang JD, Selleck W, Striker S, Hipschman NA, Kofman R, Karnezis AN**, Kommoss FKF**, Kommoss F, Wendt JR, Facista SJ, Hendricks WPD, Orlando KA, Pirrotte P, Raupach EA, Zismann VL, Wang Y, Huntsman DG, Weissman BE, Trent JM. Super-enhancers and efficacy of triptolide in small cell carcinoma of the ovary hypercalcemic type. iScience. 2025 Jan 7;28(2):111770. (IF 4.1)
61. Lange S*, Lisiecki H*, Kreutzfeldt S, Heining C, Weiss L, Westphalen CB, **Stenzinger A**, Hübschmann D, Jesinghaus M, Glimm H, Fröhling S, Pfarr N, Schlitter AM. Precision oncology for advanced-stage adenocarcinoma of the appendix: comprehensive molecular characterisation identifies actionable lesions and potential predictive biomarkers. BMJ Open Gastroenterol. 2025 Aug 21;12(1): e001671. (IF 2.9)
62. Li S, Li H, Bennewitz K, Poschet G, Buettner M, **Hausser I**, Szendroedi J, Nawroth PP, Kroll J. Combined loss of glyoxalase 1 and aldehyde dehydrogenase 3a1 amplifies dicarbonyl stress, impairs proteasome activity resulting in hyperglycemia and activated retinal angiogenesis. Metabolism. 2025 Apr;165:156149. (IF 2.7)

63. Lim B*, Kamal A*, Gomez Ramos B, Adrian Segarra JM, Ibarra IL, Dignas L, Kindinger T, **Volz K,** Rahbari M, Rahbari N, Poisel E, Kafetzopoulou K, **Böse L**, **Breinig M**, Heide D, Gallage S, Barragan Avila JE, **Wiethoff H**, Berest I, Schnabellehner S, Schneider M, Becker J, Helm D, Grimm D, Mäkinen T, **Tschaharganeh DF**, Heikenwalder M, Zaugg JB, Mall M. Active repression of cell fate plasticity by PROX1 safeguards hepatocyte identity and prevents liver tumorigenesis. Nat Genet. 2025 Mar;57(3):668-679. (IF 29.0)

64. Llaó-Cid L*, Wong J*, Fernandez Botana I, Paul Y, Wierz M, Pilger LM, Floerchinger A, Tan CL, Gonder S, Pagano G, Chazotte M, Bestak K, Schifflers C, Iskar M, Roider T, Czernilofsky F, Bruch PM, Mallm JP, Cosma A, Campton DE, Gerhard-Hartmann E, Rosenwald A, Colomer D, Campo E, **Schapiro D**, Green EW, Dietrich S, Lichter P, Moussay E, Paggetti J*, Zapatka M, Seiffert M. Integrative multi-omics reveals a regulatory and exhausted T-cell landscape in CLL and identifies galectin-9 as an immunotherapy target. Nat Commun. 2025 Aug 7;16(1). (IF 15.7)

65. Luchini C, Matkowskyj KA, Kuwata T, Longacre TA, **Schirmacher P**, Takamatsu M, Rüschoff J, Fassan M. Claudin-18.2 immunohistochemical evaluation in pancreatic cancer specimens: review and recommendations for routine testing and scoring. Virchows Arch. 2025 Sep;487(3):487-499. (IF 3.1)

66. Lutz R, Poos AM, Solé-Boldo L, John L, Wagner J, Prokoph N, Baertsch MA, Vonficht D, Palit S, **Brobeil A, Mechtersheimer G,** Hildenbrand N, Hemmer S, Steiger S, Horn S, Pepke W, Spranz DM, Rehnitz C, Sant P, Mallm JP, Friedrich MJ, Reichert P, Huhn S, Trumpp A, Rippe K, Haghverdi L, Fröhling S, Müller-Tidow C, Hübschmann D, Goldschmidt H, Willimsky G, Sauer S, Raab MS, Haas S, Weinhold N. Bone marrow breakout lesions act as key sites for tumor-immune cell diversification in multiple myeloma. Sci Immunol. 2025 Feb 7;10(104):eadp6667. (IF 16.4)

67. Malapelle U, Chen CC, de Álava E, Hofman P, **Kazdal D**, Kim TJ, Lim TKH, Ryška A, Saetta AA, Schuuring E, Troncone G, Biscuola M, Chen YL, Tan GS, Marquette CH, Michelli M, Ter Elst A, Vošmiková H, Kapp J, Gonzalez-McQuire S, Giannopoulou A, Franzini JM, Aramburu VLR, Baggi A, **Stenzinger A**. Costs of biomarker testing in advanced non-small cell lung cancer: a global study comparing next-generation sequencing and single-gene testing. J Pathol Clin Res. 2025 Mar;11(2): e70018. (IF 3.7)

68. Marinkovic E*, Chen M*, Schubert N, Dogan Dar E, **Poth T,** Leung JY, Lohre J, Sahni JM, Tun C, Rajeswaran P, Mehlo-Jensen T, Perng O, Hill CM, Sivakumar P, Barnes MJ, Malik R, Behrendt R, Roers A. Systemic Inactivation of TREX1 Induces Selective Inflammation of the Tumor Microenvironment and Invigorated T-cell-Mediated Tumor Control. Cancer Res. 2025 Aug 1;85(15):2876-2889. (IF 16.6)

69. Matias-Guiu X, Raspollini MR, Kulka J, Ryska A, Al Dieri R, **Schirmacher P**; European Society of Pathology (ESP). The role of the pathologist in the design and conducting of biomarker-driven clinical trials in cancer: position paper of the European Society of Pathology. Virchows Arch. 2025 Feb;486(2):207-214. (IF 3.1)

70. Milenkovic I, Cruciani S, Llovera L, Lucas MC, Medina R, Pauli C, Heid D, Muley T, Schneider MA, Klotz LV**, Allgäuer M**, Lattuca R, Lafontaine DLJ, Müller-Tidow C, Novoa EM. Epitranscriptomic rRNA fingerprinting reveals tissue-of-origin and tumor-specific signatures. Mol Cell. 2025 Jan 2;85(1):177-190.e7. (IF 16.6)

71. Möhrmann L, Rostock L, Werner M, Oleś M, Arnold JS, Paramasivam N, Jöhrens K, Rupp L, Schmitz M, Richter D, Uhrig S, Fröhlich M, Hutter B, Hüllein J, Jahn A, Arlt M, Möhrmann EE, Hanf D, Gieldon L, Kreutzfeldt S, Heilig CE, Teleanu MV, Lipka DB, Beck K, Baude-Müller A, Mock A, Jelas I, Rieke DT, Wiesweg M, Brandts C, Boerries M, Illert AL, Desuki A, Kindler T, Krackhardt AM, Westphalen CB, Christopoulos P, Apostolidis L, **Stenzinger A, Allgäuer M, Neumann O**, Kerle IA, Horak P, Heining C, Grosch H, Schröck E, Hübschmann D, Fröhling S,

Glimm H. Genomic landscape and molecularly informed therapy in thymic carcinoma and other advanced thymic epithelial tumors. Med. 2025 Jun 13;6(6):100612. (IF 11.8)

72. Musa J, Willis F, Rompen IF, Harnoss JC, **Grünewald TGP,** Al-Saeedi M, Büchler MW, Schneider M. Histology-driven tailoring of surgical approaches in retroperitoneal soft tissue sarcoma: retrospective cohort study. BJS Open. 2025 May 7;9(3): zraf050. (IF 4.5)
73. Mutschler CH, Seybold B, Aschauer S, **Englert N, Weis CA, Poth T**, Cetiner D, Wielpütz MO, Kehr D, Weigand MA, Kalenka A, Fiedler-Kalenka MO. Optimizing Positive End-Expiratory Pressure in Asymmetric Acute Lung Injury in a Porcine Model: The Role of Transpulmonary Pressure. Int J Mol Sci. 2025 Oct 14;26(20):9985. (IF 4.9)
74. Ngeow J, Chiang J, Astiazaran-Symonds E, Balmaña J, Cass I, **Kommoss FKF**, Foulkes WD, James PA, Katcher A, Klugman S, Livinski AA, Mak JS, Voian N, Wick MJ, Tischkowitz M, Pal T, Stewart DR, Hanson H; ACMG Professional Practice and Guidelines Committee. Electronic address: documents@acmg.net. Management of individuals with heterozygous germline pathogenic variants in RAD51C, RAD51D, and BRIP1: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2025 Nov;27(11):101557. (IF 6.2)
75. Ngo C, Colmet-Daage L, Vibert J, Hénon C, Pissaloux D, Valent A, Xiang Jin J, Brillet R, Masliah-Planchon J, Pierron G, Lacroix L, Rouleau E, Roussel-Simonin C, Lecorgne L, Astier C, Garrido M, Bahleda R, Verret B, Cesne AL, Honore C, Faron M, Herman Fridman W, Sautès-Fridman C, Coindre JM, Scoazec JY, Waterfall JJ, Bourdeaut F, **Grünewald TGP,** Blay JY, Tirode F, Postel-Vinay S. Multi-omics profiling identified two epithelioid sarcoma molecular subtypes with distinct signaling and immune characteristics. Cancer Commun (Lond). 2025 Dec;45(12):1760-1766. (IF 24.9)
76. Niedermaier B, **Allgäuer M**, Muley T, Schneider MA, Eichhorn ME, Winter H, Klotz LV. Intratumor Heterogeneity Predicts Prognosis in Lepidic Predominant Lung Adenocarcinoma. Thorac Cancer. 2025 Jan;16(1):e15536. (IF 2.3)
77. Niedermaier B, Rolf E, **Allgäuer M**, Klotz LV, Schneider MA, Yuskaeva K, Eichhorn ME, Winter H. Prognostic impact of lepidic growth in intermediate and high-grade lung adenocarcinoma. Lung Cancer. 2025 Aug;206:108674. (IF 4.4)
78. Nitschkowski D, Vierbuchen T, Heine H, Behrends J, Reiling N, Reck M, Rabe KF, Kugler C, Ammerpohl O, Drömann D, Muley T, **Kriegsmann M**, Stathopoulos GT, Arendt KAM, Goldmann T, Marwitz S. SMAD2 linker phosphorylation impacts overall survival, proliferation, TGFβ1-dependent gene expression and pluripotency-related proteins in NSCLC. Br J Cancer. 2025 Jul;133(1):52-65. (IF 6.8)
79. Nuhic S, Werner P, **Kazdal D, Menzel M, Stenzinger A**, Martens UM, Fegeler C, **Budczies J**, Sigle S. Whole Exome Sequencing on FHIR: Towards Adoption in Clinical Practice for Precision Oncology Pipelines. Stud Health Technol Inform. 2025 Sep 3;331:153-161 (IF 0.9)
80. Olmedo-Pelayo J, Granado-Calle E, Delgado-Bellido D, Lobo-Selma L, Jordan-Perez C, Monteiro-Amaral AT, Ehlers AC, Ohmura S, Garcia-Dominguez DJ, Mackintosh C, Carcaboso AM, Alonso J, Machado I, Llombart-Bosch A, Scotlandi K, **Grünewald TGP**, Gomez-Herreros F, de Alava E. EWS::FLI1-DHX9 interaction promotes Ewing sarcoma sensitivity to DNA topoisomerase 1 poisons by altering R-loop metabolism. Oncogene. 2025 Oct;44(38):3537-3552. (IF 7.3)
81. **Ourailidis I*,** Stögbauer F*, Zhou Y*, **Beck S, Romanovsky E**, Eckert S, Wollenberg B, Wirth M, Steiger K, Kuster B, Gires O, **Stenzinger A**, **Schirmacher P,** Weichert W, Kuhn PH, Boxberg M, **Budczies J**. Multi-omics analysis to uncover the molecular basis of tumor budding in head and neck squamous cell carcinoma. NPJ Precis Oncol. 2025 Mar 13;9(1):73 (IF 8.0)

82. Pixberg C, Maurer C, Smetanay K, Straßl L, Hlevnjak M, Zapatka M, Wagner CV, Yazdanparast H, Kurzawa J, Erben V, Feng F, Hong C, Hübschmann D, Buschhorn L, Suppelna JP, Michel L, Heublein S, Fremd C, Zivanovic O, **Sinn P, Stenzinger A**, Haidinger R, Schumacher-Wulf E, Ditsch N, Loibl S, Fröhling S, Link T, Wimberger P, Blohmer JU, Huebner H, Fasching PA, Janni W, Schlenk RF, Thewes V, Lichter P, Schneeweiss A. COGNITION-GUIDE - Genomics-Guided Targeted Post-Neoadjuvant Therapy in Patients with Early Breast Cancer: Study Design of a Multicenter, Open-Label, Umbrella Phase II Study. Geburtshilfe Frauenheilkd. 2025 Apr 10;85(6):611-619. (IF 2.0)

83. **Puzalkova AV*, Hofmann K*, Pfeffer T, Klein IM,** Mehrabi A, Merle U, **Stenzinger A, Penzel R, Flechtenmacher C, Schirmacher P**. High relevance of invasive fungal disease in chronic liver transplant failure: a comprehensive cross-sectional study. Virchows Arch. 2025 Aug;487(2):413-422. (IF 3.1)

84. Rauber C, Roberti MP, Vehreschild MJ, Tsakmaklis A, Springfeld C, Teufel A, Ettrich T, Jochheim L, Kandulski A, Missios P, Mohr R, Reichart A, Waldschmidt DT, Sauer LD, Sander A, **Schirmacher P**, Jäger D, Michl P, Dill MT. Protocol: Faecal microbiota transfer in liver cancer to overcome resistance to atezolizumab/bevacizumab - a multicentre, randomised, placebo-controlled, double-blind phase II trial (the FLORA trial). BMJ Open. 2025 Sep 9;15(9):e097802. (IF 2.3)

85. Reimer T, Kuehn T, Mueller V, Ditsch N, Fehm T, Albert US, Bartsch R, Bauerfeind I, Bjelic-Radisic V, Blohmer JU, Budach W, Dall P, Fallenberg EM, Fasching PA, Friedrich M, Gerber B, Gluz O, Harbeck N, Hartkopf A, Heil J, Hoerner-Rieber J, Huober J, Janni W, Kreipe HH, Krug D, Kuemmel S, Loibl S, Lueftner D, Lux MP, Maass N, Mundhenke C, Park-Simon TW, Reinisch M, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Schuetz F, **Sinn HP**, Solbach C, Solomayer EF, Stickeler E, Thomssen C, Untch M, van Mackelenbergh M, Witzel I, Woeckel A, Wuerstlein R, Banys-Paluchowski M, Thill M. AGO Breast Commission recommendations for the surgical therapy of breast cancer: Working Group on Gynecologic Cancers (AGO) update 2025. Eur J Surg Oncol. 2025 Nov;51(11):110445. (IF 2.9)

86. Reinhard J*, Polke M*, Buschulte K, Eichinger M, Heußel CP, Güttlein M, Michels-Zetsche JD, Wielpütz MO, Kahnert K, Kontogianni K, Klotz LV, **Allgäuer M**, Herth FJ, Eberhardt R, Kreuter M, Trudzinski FC. Sex-specific aspects in a population of patients undergoing evaluation for interstitial lung disease with transbronchial cryobiopsy. Sci Rep. 2025 Apr 5;15(1):11730. (IF 3.9)

87. Reiser J, Albers J, Svetlove A, Mertiny M, **Kommoss FKF, Schwab C**, Schneemann A, Tromba G, Wacker I, Curticean RE, Schroeder RR, Kauczor HU, Wielpütz MO, Dullin C*, Wagner WL*. Integrated 3D imaging of FFPE lung tissue combining microCT, light and electron microscopy allows for contextualized ultrastructural and histological analysis. Sci Rep. 2025 May 28;15(1):18656 (IF 3.9)

88. **Ritz T*,** Tanevski J*, Baues J, Loosen SH, Luedde T, Neumann U, Boor P, **Schirmacher P**, Saez-Rodriguez J, **Longerich T**. Proteomic subtyping highlights tumor heterogeneity of human HCC. Virchows Arch. 2025 Nov;487(5):959-969. (IF 3.1)

89. Roberti MP, Charoentong P, Lyu Y, Meyer M, Eichmüller SB, Schmidt P, Momburg F, Cetin M, Hartmann F, Valous NA, **Stenzinger A,** Michel L, Lichter P, Schneeweiss A, Thewes V, Fremd C, Zörnig I, Jäger D. Isolation of a tumor neoantigen specific CD8+ TCR from a skin biopsy of a vaccination site. Oncoimmunology. 2025 Dec;14(1):2457793. (IF 6.3)

90. Roesch RM, Schnorbach J, Klotz LV, Griffo R, Thomas M, **Stenzinger A,** Christopoulos P, **Allgaeuer M**, Schneider M, Schuler M, Wiesweg M, Schramm A, Bölükbas S, Doerr F, Hegedüs B, Cvetkovic J, Kirchner M, Eichhorn ME, Winter H, Bozorgmehr F, Eichhorn F. NeoTRACK trial: Neoadjuvant TiRagolumab, Atezolizumab and Chemotherapy - dissection

of IO- efficacy in NSCLC by longitudinal tracKing - protocol of a non-randomised, open-label, single-arm, phase II study. BMJ Open. 2025 Mar 27;15(3):e096617. (IF 2.3)

91. **Romanovsky E***, Choudhary A*, Peles D, Abu-Akel A, Stern S. Uncovering convergence and divergence between autism and schizophrenia using genomic tools and patients' neurons. Mol Psychiatry. 2025 Mar;30(3):1019-1028. (IF 10.1)
92. **Romanovsky E, Menzel M, Kluck K, Beck S, Ball M, Schirmacher P, Kazdal D, Stenzinger A, Budczies J.** CG>TG mutation frequency as negative predictor of homologous recombination deficiency in ovarian and breast cancer. Commun Biol. 2025 Jul 29;8(1):1126. (IF 5.1)
93. Rompen IF, Nerz D, Crnovrsanin N, Hu W, Zimmer S, Musa J, Haag GM, **Fiedler T, Longerich T**, Al-Saeedi M, Sisic L, Schmidt T, Nienhüser H. The role of placental growth factor as a biomarker in patients with resectable gastric cancer. J Gastrointest Surg. 2025 Jun;29(6):102051. (IF 2.4)
94. Rosing F, Plath M, Proctor T, Höfler D, Alt Y**, Lucena-Porcel C**, Waterboer T, Hess J, Plath K, Schroeder L. Post-treatment monitoring of surgically treated oropharyngeal squamous cell carcinoma patients using human papillomavirus cell-free DNA. Oral Oncol. 2025 Apr;163:107225. (IF 3.9)
95. Salié H, Wischer L, D'Alessio A, Godbole I, Suo Y, Otto-Mora P, Beck J, **Neumann O, Stenzinger A, Schirmacher P**, Fulgenzi CAM, Blaumeiser A, Boerries M, Roehlen N, Schultheiß M, Hofmann M, Thimme R, Pinato DJ, **Longerich T**, Bengsch B. Spatial single-cell profiling and neighbourhood analysis reveal the determinants of immune architecture connected to checkpoint inhibitor therapy outcome in hepatocellular carcinoma. Gut. 2025 Feb 6;74(3):451-466. (IF 26.2)
96. Sater S, Bifulco CB, Rodriguez-Canales J, Yeong J, Akturk G, Angelo M, Ballesteros-Merino C, Bankhead P, Basu S, Blando JM, Brajkovic S, Cassano M, Chen BJ, Coskun AF, Cottrell TR, De Andrea CE, Edwards RH, Egelston C, Engle LL, Ernstoff MS, Fan R, Feldman M, Fox BA, Galon J, Gartrell R, Gnjatic S, Green BF, Gulley JL MD,, Hellebust A, Hewitt S, Hollmann TJ, Horn LA, Howat WJ, Hoyt CC, Jensen SM, Kulasinghe A, Lassoued W, Lott S, Mansfield J, Marwitz S, Netto G, Page DB, Parra E, Rimm DL, Rodig SJ, Salgado R, **Schapiro D**, Schalper KA MD,, Sunshine JC, Surace MJ, Szalay AS, Thurin M, Villasboas JC, Wharton K, Wistuba II, Yearley JH, Yuan Y, Zaki G, Ziai J, Taube JM. Society for Immunotherapy of Cancer: Standards for Reporting of Multiplex Immunohistochemistry/Immunofluorescence Assays (STORMI). J Immunother Cancer. 2025 Dec 21;13(12): e012280. (IF 10.6)
97. Schmitz D, Prax S, Kliment M, Gocke F, **Kazdal D, Allgäuer M**, **Penzel R, Kirchner M, Neumann O,** Sültmann H, **Budczies J, Schirmacher P, Bergmann F**, Ritz JP, Hinze R, Grassmann F, Rudi J, **Stenzinger A, Volckmar AL**. Differentiating Main-Duct IPMN from Chronic Pancreatitis Using Next-Generation Sequencing of Main Pancreatic Duct Fluid: A Pilot Study. Diagnostics (Basel). 2025 Aug 5;15(15):1964. ( IF 3.3)
98. Schneider AT, Koppe C, Crouchet E, Papargyriou A, Singer MT, Büttner V, Keysberg L, Szydlowska M, Jühling F, Moehlin J, Chen MC, Leone V, Mueller S, Neuß T, Castoldi M, Lesina M, **Bergmann F**, Hackert T, Steiger K, Knoefel WT, Zaufel A, Kather JN, Esposito I, Gaida MM, Ghallab A, Hengstler JG, Einwächter H, Unger K, Algül H, Gassler N, Schmid RM, Rad R, Baumert TF, Reichert M, Heikenwalder M, Kondylis V, Vucur M, Luedde T. A decision point between transdifferentiation and programmed cell death priming controls KRAS-dependent pancreatic cancer development. Nat Commun. 2025 Feb 19;16(1):1765. (IF 15.7)
99. Schulte LA, Beck A, Marienfeld R, Azoitei N, Barth TF, Beutel A, Benes V, Büchler MW, Gaisa NT, Kilani K, Giese N, Michalski CW, Möller P, Perkhofer L, Rausch T, Repky S, Roger E, Scheible J, Seufferlein T, **Schirmacher P**, Berger AW, Hackert T, Kleger A. Unveiling the

intriguing relationship: oncogenic KRAS, morphological shifts, and mutational complexity in pancreatic mucinous cystic neoplasms. J Pathol. 2025 Apr;265(4):401-407. (IF 5.2)

100. Schütz V, Geisler C, Rath M, Böning S, Treber T, **Stenzinger A, Brobeil A**, Reinhard O, Duensing A, Duensing S, Hohenfellner M, Görtz M. DATA 5.0-Data Acquisition, Translation & Analysis-a prospective urooncological data warehouse for the 21st century. Front Digit Health. 2025 Mar 27;7:1530321. (IF 3.8)
101. Schwarz D, Le Marois M, Sturm V, Peters AS, Longuespée R, Helm D, Schneider M, Eichmüller B, Hidmark AS, Fischer M, Kender Z, **Schwab C, Hausser I**, Weis J, Dihlmann S, Böckler D, Bendszus M, Heiland S, Herzig S, Nawroth PP, Szendroedi J, Fleming T. Exploring Structural and Molecular Features of Sciatic Nerve Lesions in Diabetic Neuropathy: Unveiling Pathogenic Pathways and Targets. Diabetes. 2025 Jan 1;74(1):65-74. (IF 7.5)
102. Schwerd-Kleine P, Würth R, Cheytan T, Michel L, Thewes V, **Gutjahr E**, **Seker-Cin H, Kazdal D**, Neuberth SJ, Thiel V, Schwickert J, Vorberg T, Wischhusen J, **Stenzinger A**, Zapatka M, Lichter P, Schneeweiss A, Trumpp A, Sprick MR. Biopsy-derived organoids in personalised early breast cancer care: Challenges of tumour purity and normal cell overgrowth cap their practical utility. Int J Cancer. 2025 Jun 1;156(11):2200-2209. (IF 4.7)
103. Sebode M*, Bantel H, Baumann U, Bufler P, Dold L, Hohenester S, Keitel-Anselmino V, Klein R, Kremer AE, Lynen Jansen P, **Schirmacher P**, Schramm C, Sterneck M, Strassburg CP, Weiler-Normann C, Lohse AW*. S3-Leitlinie „Seltene Lebererkrankungen (LeiSe LebEr) – Autoimmune Lebererkrankungen von der Pädiatrie bis zum Erwachsenenalter“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) [S3 guideline "Rare liver diseases (LeiSe LebEr) - Autoimmune liver diseases from paediatrics to adulthood" of the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS)]. Z Gastroenterol. 2025 Jun;63(6):604-688. German. ( IF 1.6)
104. Shaalan W, Haßdenteufel K, Hoppe F, **Sinn P**, Togawa R, Tretschock LM, Batarseh D, Ylitalo H, Hassan N, Schäfgen B, Hennigs A, Smetanay K, Schneeweiss A, Nees LK, Riedel F, Zivanovic O. Implementation of Robotic-Assisted Surgery for the Treatment of Patients with Endometrial Carcinoma. Cancers (Basel). 2025 Sep 23;17(19):3097. (IF 4.4)
105. Simpson C, Tabatsky E, Rahil Z, Eddins DJ, Tkachev S, Georgescauld F, Papalegis D, Culka M, Levy T, Gregoretti I, Meehan C, Schiller C, Bestak K, **Schapiro D**, Chernyshev A, Walther G, Ghosn EEB, Orlova D. Lifting the curse from high-dimensional data: automated projection pursuit clustering for a variety of biological data modalities. Gigascience. 2025 Jan 6;14:giaf052. (IF 3.9)
106. Siqin S, Rahbari M, Ernst C, Grewe I, Gunst K, Neßling M, Kaden S, Richter K, Häfele L, Feuerbach L, Krunic D, Tessmer C, Hofmann I, Birgin E, **Brobeil A**, Rahbari N, Heikenwälder M, Bund T. Expression of Bovine Meat and Milk Factor in Hepatocellular Carcinoma and Colorectal Liver Metastasis Patients. J Med Virol. 2025 Aug;97(8):e70507. (IF 4.6)
107. Steen S, Horn D**, Flechtenmacher C**, Hoffmann J, Freier K, Ristow O, Hess J, Moratin J. Expression analysis of SOX2 and SOX9 in patients with oral squamous cell carcinoma. Head & Neck. 2025 Feb;47(2):437-451. (IF 2.2)
108. **Stenzinger A**, Westphalen CB, **Budczies J, Kazdal D, Ploeger C, Altbürger C**, Evert M, Malek N, **Schirmacher P**, Klauschen F. Comprehensive genomic profiling requires a blended ecosystem of learning healthcare and clinical trials. Br J Cancer. 2025 Jun;132(10):866-868. (IF 6.8)
109. Stenzinger M, **Beck S**, **Ourailidis I, Volckmar AL**, Paramasivam N, Ahadova A, Portilla ALL, La Yen P, Nilsson B, Bermejo JL, Bonig H, **Budczies J**. Contribution of genetics to hematopoietic stem cell mobilization: a genome-wide association study of 564 healthy donors mobilized

with granulocyte colony-stimulating factor. Haematologica. 2025 Nov 1;110(11):2683-2690. (IF 7.9)

110. Stögbauer F, Wirth M, Lauterbach M, Wollenberg B, Schmidl B, Hoch CC, **Ourailidis I**, Hess J, Eckstein M, Hartmann A, Iro H, Gostian AO, Balk M, Jesinghaus M, Ribbat-Idel J, Sailer VW, Perner S, Bruchhage KL, Hoffmann M, Lükewille L, Stuhlmann-Laeisz CM, Röcken C, Mogler C, **Budczies J***, Boxberg M*. Tumor budding and lymphovascular invasion as prognostic factors in p16-positive oropharyngeal squamous cell carcinomas. Br J Cancer. 2025 Feb;132(2):212-221. (IF 6.8)

111. Tagore S*, Caprio L*, Amin AD*, Bestak K*, Luthria K, D'Souza E, Barrera I, Melms JC, Wu S, Abuzaid S, Wang Y, Jakubikova V, Koch P, Brodtman DZ, Bawa B, Deshmukh SK, Ebel L, Ibarra-Arellano MA, Jaiswal A, Gurjao C, Biermann J, Shaikh N, Ramaradj P, Georgis Y, Lagos GG, Ehrlich MI, Ho P, Walsh ZH, Rogava M, Politis MG, Biswas D, Cottarelli A, Rizvi N, Shu CA, Herzberg B, Anandasabapathy N, Sledge G, Zorn E, Canoll P, Bruce JN, Rizvi NA, Taylor AM, Saqi A, Hibshoosh H, Schwartz GK, Henick BS, Chen F, **Schapiro D***, Shah P*, Izar B*. Single-cell and spatial genomic landscape of non-small cell lung cancer brain metastases. Nat Med. 2025 Apr;31(4):1351-1363. (IF 50.0)

112. Tanevski J, Vulliard L, Ibarra-Arellano MA, **Schapiro D**, Hartmann FJ, Saez-Rodriguez J. Learning tissue representation by identification of persistent local patterns in spatial omics data. Nat Commun. 2025 Apr 30;16(1):4071. (IF 15.7)

113. Tang Y*, Niu Y*, Chen Y*, Zhou X*, **Hu Y**, Sun L, Xiong Y, Xu Y, Wang Q, Wang Y, Guo L. Targeting FOXP1 phase separation in small cell lung cancer mechanisms of chemotherapy resistance. Commun Biol. 2025 Mar 13;8(1):431. (IF 5.1)

114. Tauch S, Hey J, Kast B, Gengenbacher N, Weiß L, Sator-Schmitt M, Lohr S, **Brobeil A, Schirmacher P**, Utikal J, Augustin HG, Plass C, Angel P. A Unique Signature for Cancer-Associated Fibroblasts in Melanoma Metastases. Pigment Cell Melanoma Res. 2025 Mar;38(2): e70002. (IF 2.6)

115. Thiel V*, Renders S*, Panten J*, Dross N, Bauer K, Azorin D, **Henriques V, Vogel V**, Klein C, Leppä AM, Barriuso Ortega I, Schwickert J, **Ourailidis I**, Mochayedi J, Mallm JP, Müller-Tidow C, Monyer H, Neoptolemos J, Hackert T, Stegle O, Odom DT, Offringa R**, Stenzinger A**, Winkler F, Sprick M, Trumpp A. Characterization of single neurons reprogrammed by pancreatic cancer. Nature. 2025 Apr;640(8060):1042-1051. ( IF 48.5)

116. Thunnissen E, Blaauwgeers H, Filipello F, Lissenberg-Witte B, Minami Y, Noguchi M, Quesne JL, Papotti MG, Flieder DB, Pelosi G, Sansano I, Berezowska S, Ryška A, Brcic L, Motoi N, Nakatani Y, Kuempers C, Hofman P, Hofman V, Dale VG, Rossi G, Ambrosi F, Matsubara D, Ishikawa Y, Weynand B, Calabrese F, Pezzuto F, Kern I, Nicholson S, Mutka A, Dacic S, Beasley MB, Arrigoni G, Timens W, Ooft M, Brinkhuis M, Bulkmans N, Britstra R, Vreuls W, Jones KD, von der Thüsen JH, Hager H, Perner S, Moore D, Leonte DG, Al-Janabi S, Schønau A, **Neumann O, Kluck K, Ourailidis I, Ball M, Budczies J, Kazdal D, Stenzinger A.** A reproducibility study on invasion in small pulmonary adenocarcinoma according to the WHO and a modified classification, supported by biomarkers. Lung Cancer. 2025 Jan;199: 108060. Erratum in: Lung Cancer. 2025 Jun;204:108488. (IF 4.4)

117. Tietzova I, Sochorova D, Triska P, Rancourt RC, Omelka M, Parobkova E, **Allgäuer M**, Schneider MA, Senghas K, Klotz LV, Tesarova M. Identification of a novel RSPO1-NUMT insertion in a LUAD patient cohort and the challenges and insights into NUMT detection highlighting the importance of reference genomes and population databases. Transl Lung Cancer Res. 2025 Oct 31;14(10):4560-4570. (IF 3.5)

118. Toberer F*, Winkler JK*, Atienza Fernandez L, Adams L, **Brobeil A, Tóth M**, Enk AH, Becker JC, Lonsdorf A. Inhibitory Immune Checkpoints beyond Programmed Cell Death Ligand 1 in

Merkel Cell Carcinoma: Abundant Expression of TIGIT Independent of the Presence of Merkel Cell Polyoma Virus. Acta Derm Venereol. 2025 Jul 1; 105: adv42882. (IF 3.7)

119. **Tóth M, Wan S, Schmitt J, Birner P, Wei T, von Bubnoff F,** de la Torre C, **Thomann S, Pinna F**, **Schirmacher P, Weiler SME, Breuhahn K**. The Cell Polarity Protein MPP5/PALS1 Controls the Subcellular Localization of the Oncogenes *YAP* and *TAZ* in Liver Cancer. Int J Mol Sci. 2025 Jan 14;26(2):660. (IF 4.9)
120. Tulessin M, Beer L, **Roessler S**, Beckers A, Castven D, Calvisi DF, Chen X, Lange S, Pfarr N, Marquardt J, Wirtz TH, Berres ML, Steiger K, Groll T, Mogler C. Detailed Characterization and Comparison of Mouse Models for Cholangiocarcinoma. Lab Invest. 2025 Dec;105(12):104242. (IF 4.2)
121. Wei N, Mathy RM, Chang DH, Mayer P, Liermann J, Springfeld C, Dill MT, **Longerich T,** Lurje G, Kauczor HU, Wielpütz MO*, Öcal O*. Longitudinal CE-MRI-based Siamese network with machine learning to predict tumor response in HCC after DEB-TACE. Cancer Imaging. 2025 Aug 19;25(1):104. (IF 3.5)
122. Weishaupt H, Besusparis J, **Weis CA**, Porubsky S, Laurinavičius A, Leh S. Unsupervised learning for labeling global glomerulosclerosis. Comput Biol Med. 2025 Sep;196(Pt B):110719. (IF 6.3)
123. Wieke J, Jurcic C, Kaczorowski A, Böning S, **Kirchner M, Schwab C**, Schütz V, Hohenfellner M, Duensing A, **Stenzinger A**, Duensing S. Extensive genotype-phenotype heterogeneity in renal cell carcinoma - a proof-of-concept study. Front Oncol. 2025 Apr 25;15:1551077. (IF 3.3)
124. Wiesweg M, Alaffas A, Rasokat A, Saalfeld FC, Rost M, Assmann C, Herster F, Hilbrandt M, Griesinger F, Kron A, Roeper J, Glanemann F, Kropf-Sanchen C, Reck M, Kulhavy J, **Stenzinger A**, Wolf J, Sebastian M, Schuler M, Wermke M, Frost N, Kopp HG, Christopoulos P, Scheffler M. Treatment Sequences in BRAF-V600-Mutated NSCLC: First-Line Targeted Therapy Versus First-Line (Chemo-) Immunotherapy. J Thorac Oncol. 2025 Sep;20(9):1328-1335. (IF 20.8)
125. Wiesweg M, Küter C, Schnorbach J, Keyl J, Metzenmacher M, Cvetkovic J, Saalfeld FC, Glanemann F, Eberhardt W, Oezkan F, Theegarten D, **Stenzinger A**, Darwiche K, Koschel D, Herth F, Bölükbas S, Winter H, Weykamp F, Wermke M, Stuschke M, Plönes T, Thomas M, Schuler M, Christopoulos P. Oligometastatic non-small cell lung cancer: Impact of local and contemporary systemic treatment approaches on clinical outcome. Int J Cancer. 2025 Feb 15;156(4):776-787. (IF 4.7)
126. Wong K, Bishop JA, Weinreb I, Motta M, Del Castillo Velasco-Herrera M, Bellacchio E, Ferreira I, van der Weyden L, Boccacino JM, Lauri A, Rotundo G, Ciolfi A, Cheema S, Olvera-León R, Offord V, Droop A, Vermes I, **Allgäuer M,** Hyrcza M, Anderson E, Smith K, de Saint Aubain N, Mogler C, **Stenzinger A**, Arends MJ, Brenn T, Tartaglia M, Adams DJ. Wnt/β-catenin activation by mutually exclusive FBXW11 and CTNNB1 hotspot mutations drives salivary basal cell adenoma. Nat Commun. 2025 May 19;16(1):4657. (IF 15.7)
127. Wünnemann F, Sicklinger F, Bestak K, Nimo J, Thiemann T, Amrute JM, Nordbeck M, Hartmann N, Ibarra-Arellano MA, Tanevski J, Chazotte M, Heine C, Frey N, Lavine KJ, Coscia F, Saez-Rodriguez J, Leuschner F*, **Schapiro D***. Spatial multiomics of acute myocardial infarction reveals immune cell infiltration through the endocardium. Nat Cardiovasc Res. 2025 Oct;4(10):1345-1362. (IF 10.8)
128. Würth R, Donato E*, Michel LL*, Saini M*, Becker L*, Cheytan T, Doncevic D, Messmer T, **Gutjahr E,** Weber R, Klein C, Alborzinia H, Yildiz U, Vogel V, Hlevnjak M, Kozyulina P, Neuberth SJ, Schwerd-Kleine P, Jakab S, Pfarr N, Angeles AK, Laut AK, Karpova D, Falcone M, Hardt O, Theek B, Wagner CV, Becker M, Wagner S, Haselmayr M, Schmitt A, Müller-Tidow C, Riethdorf S, Pantel K, Zapatka M, Sültmann H, Herrmann C, Thewes V, Lichter P,

Schneeweiss A, Sprick MR, Trumpp A. Circulating tumor cell plasticity determines breast cancer therapy resistance via neuregulin 1-HER3 signaling. Nat Cancer. 2025 Jan;6(1):67-85. (IF 28.5)

129. Yuan T, Edelmann D, Moreno V, Georgii E, de Andrade E Sousa LB, Pelin H, Jiang X, Kather JN, Tagscherer KE, **Roth W**, Bewerunge-Hudler M, **Brobeil A,** Kloor M**,** Bläker H, Brenner H, Hoffmeister M. Identification and external validation of tumor DNA methylation panel for the recurrence risk stratification of stage II colon cancer. Transl Oncol. 2025 Jul;57: 102405 (IF 4.1)
130. Yuan T, Tagscherer KE, **Roth W**, Bewerunge-Hudler M, **Brobeil A**, Kloor M, Bläker H, Brenner H, Hoffmeister M. Methylation-based alcohol consumption scores as prognostic biomarkers in colorectal cancer: Insights from a population-based cohort. Int J Cancer. 2025 Dec 15;157(12):2521-2531. (IF 4.7)
131. Yuan T, Tagscherer KE, **Roth W,** Bewerunge-Hudler M**, Brobeil A,** Kloor M, Bläker H, Brenner H, Hoffmeister M. Methylation-based smoking signatures in blood and tissue samples for the prediction of self-reported smoking status and mortality in patients with colorectal cancer. Clin Epigenetics. 2025 Jul 3;17(1):113. (IF 4.4)
132. Zerdes I, Kamali C, Johannsdottir B, Blasi M, Assmann C, **Kazdal D, Stenzinger A**, Skribek M, Ekman S, Christopoulos P, Tsakonas G. A novel clinical brain prognostic index for KRAS-mutated lung cancer and brain metastases (KRAS-BPI): Real-world evidence from two large European centers. Lung Cancer. 2025 Jan;199:108065. (IF 4.4)
133. Zhang KS, Neelsen CJO, Wennmann M, Hielscher T, Kovacs B, Glemser PA, Görtz M, **Stenzinger A**, Maier-Hein KH, Huber J, Schlemmer HP, Bonekamp D. In vivo variability of MRI radiomics features in prostate lesions assessed by a test-retest study with repositioning. Sci Rep. 2025 Aug 13;15(1):29703. (IF 3.9)
134. Zhang Q*, Zhang Y*, Fu C*, He X, Huang Z, Wu G, Wei T, Jin W, Yan L, Wu M, Peng G, Fan L, Li M, Guo Y, Bi J, Bai Y, **Roessler S**, Yan GR, Liu L. CSTF2 Supports Hypoxia Tolerance in Hepatocellular Carcinoma by Enabling m6A Modification Evasion of PGK1 to Enhance Glycolysis. Cancer Res. 2025 Feb 1;85(3):515-534. (IF 16.6)
135. Zhang X, Gschwind J, Erben V, Bennewitz K, Li X, Sticht C, Poschet G, **Hausser I**, Fleming T, Szendroedi J, Nawroth PP, Kroll J. Endogenous acrolein accumulation in akr7a3 mutants causes microvascular dysfunction due to increased arachidonic acid metabolism. Redox Biol. 2025 Jun;83: 103639. (IF 11.9)
136. Zhou J*, He M*, Zhao Q*, Shi E*, Wang H, Ponkshe V, Song J, Wu Z, Ji D, Kranz G, Tscherne A, Schwenk-Zieger S, Razak NA, Hess J, Belka C, Zitzelsberger H, **Ourailidis I**, Stögbauer F, Boxberg M, **Budczies J**, Reichel CA, Canis M, Baumeister P, Wang H, Unger K, Mock A, Gires O. EGFR-mediated local invasiveness and response to Cetuximab in head and neck cancer. Mol Cancer. 2025 Mar 22;24(1):94 (IF 33.9)

## REVIEWS AND OTHER PUBLICATIONS

1. Alfaraidi M, **Kommoss FK**, Dallaire-Nantel LA, Sabbaghian N, Leblanc J, Zeng X, Marino TC, Foulkes WD, Fu L. *DICER1* associated cervical embryonal rhabdomyosarcoma in a 59-year-old woman. Gynecol Oncol Rep. 2025 Jan 25;58: 101683. (IF 1.3)
2. Bull EC, Singh A, Harden AM, Soanes K, Habash H, Toracchio L, Carrabotta M, Schreck C, Shah KM, Riestra PV, Chantoiseau M, Da Costa MEM, Moquin-Beaudry G, Pantziarka P, Essiet EA, Gerrand C, Gartland A, Bojmar L, Fahlgren A, Marchais A, Papakonstantinou E, Tomazou EM,

Surdez D, Heymann D, Cidre-Aranaz F, Fromigue O, Sexton DW, Herold N**, Grünewald TGP**, Scotlandi K, Nathrath M, Green D. Targeting metastasis in paediatric bone sarcomas. Mol Cancer. 2025 May 29;24(1):153. (IF 33.9)

3. Burgard C, Te Gussinklo WH, **Ritz T**, Al-Maisary S. First comprehensive case report of surgical resection of a cardiac Merkel cell carcinoma metastasis. JTCVS Tech. 2025 Jul 23;33:155-157. (IF 1.9)
4. Crnovrsanin N, Zumsande S, Rompen IF, Schiefer S, Zimmer S, Hu W, **Arnscheidt J**, **Brinkmann F, Longerich T**, Haag GM, Schmidt T, Al-Saeedi M, Sisic L, Nienhüser H. ASO Author Reflections: The Role of Beta-Blockers in Gastric Cancer-A Pathway to Personalized Therapy? Ann Surg Oncol. 2025 Jul;32(7):5202-5203. (IF 3.5)
5. **Goeppert B**, Zen Y, Valle J, Klimstra D, Deshpande V. Cholangiocarcinoma classification: current approach, relevance and challenges. J Clin Pathol. 2025 Apr 17;78(5):298-299. (IF 2.0)
6. Griffo R, Klotz LV, Brendel L, Rösch R, Niedermaier B, Schlamp K, **Kriegsmann M**, Eichhorn MM, Winter H. Pulmonary arteriovenous malformation causing lung sequestration and media infarction: a case report. Front Med (Lausanne). 2025 Feb 11;12:1490820. (IF 3.0)
7. Hofman P**, Ourailidis I, Romanovsky E**, Ilié M, **Budczies J, Stenzinger A**. Artificial intelligence for diagnosis and predictive biomarkers in Non-Small cell lung cancer Patients: New promises but also new hurdles for the pathologist. Lung Cancer. 2025 Feb;200:108110. (IF 4.4)
8. Keil F, Metzler T, Thomann S, **Albrecht T**, Mogler C. Gefäßtumoren der Leber [Vascular neoplasms of the liver]. Pathologie (Heidelb). 2025 Nov;46(6):364-372. German. (IF 0.7)
9. Maier J, **Englert N**, Bobe S. Nachwuchsforschung im Fokus : Eine neue Rubrik in Die Pathologie [Focus on young researchers : A new section in Pathology]. Pathologie (Heidelb). 2025 Nov;46(6):334-335. German. (IF 0.7)
10. Marquardt, J., Klöckner R., **Schirmacher P.**, Wedemeyer H, Holtmann L, Kerkmann M. Qualitätssicherungsinitiative zur Behandlung von Leberkrebs und biliären Karzinomen in Deutschland („QLC“). *Forum* **40**,October 2025, 338–339 (2025). (IF n/a)
11. Pouyiourou M, Bochtler T, Pauli C, Moch H, **Brobeil A**, Pantel K, **Stenzinger A**, Krämer A. Rethinking cancer of unknown primary: from diagnostic challenge to targeted treatment. Nat Rev Clin Oncol. 2025 Oct;22(10):781-799. (IF 83.2)
12. Rimassa L, Khan S, Groot Koerkamp B, **Roessler S**, Andersen JB, Raggi C, Lleo A, Nault JC, Calderaro J, Gabbi C, Kather JN, Banales JM, Bargellini I, Morement H, Krawczyk M, Farazi PA, Carpino G, Avila MA, Saborowski A, Cardinale V, Braconi C, Macias RIR. Mapping the landscape of biliary tract cancer in Europe: challenges and controversies. Lancet Reg Health Eur. 2025 Feb 19;50: 101171. (IF 13.0)
13. Rösner T, Grenz J, Schaumäker M, Cuntz S, Blank N, **Charbel A**, **Flechtenmacher C**, Michl P, Pfeiffenberger J, Boxberger M, Mohr I. Fatal Liver Failure After Herpes-Simplex-Virus-2-Induced Acute Necrotizing Hepatitis: A Case Report. Case Reports Hepatol. 2025 Jul 23;2025:1414531. ( IF n/a)
14. Schaefgen B, Buchen S, **Sinn HP.** Juvenile Fibroadenoma Detected at 2 Years and Rapid Growth at Thelarche: Case Report and Literature Review. Breast Cancer (Auckl). 2025 Sep 6;19:11782234241306209. (IF 1.9)
15. Scherl C, Ludwig S, Hesser J, MonjiAzad S, Stallkamp J, Jungbauer F, Enders F, **Weis CA**, Rotter N. Augmented Reality in der Kopf-Hals-Chirurgie [Augmented Reality in head and neck surgery]. Laryngorhinootologie. 2025 Aug;104(8):487-497. German. ( IF 1.4)
16. Schmitz D, **Stenzinger A**, Grützmann R, Esposito I, Raatschen HJ, Seufferlein TTW. The Differential Diagnosis and Management of Pancreatic Cystic Neoplasms. Dtsch Arztebl Int. 2025 Oct 31;122(22):617-622. (IF 7.2)

17. Skok K, Stift J, **Schirmacher P**, Kashofer K, Stauber R, Ranković B, Lackner K. Molecular Landscape and Treatment Paradigms of Hepatocellular and Cholangiocarcinoma: A Multinational Review. Z Gastroenterol. 2025 Sep;63(9):948-959. (IF 1.6)
18. **Stenzinger A,** Normanno N, Lamarca A, Rimassa L, Bibeau F, Taniere P, Vogel A, Hollebecque A. From barriers to solutions: an expert-based algorithm for cholangiocarcinoma and other biliary tract cancers testing in the Era of precision oncology. Expert Rev Mol Diagn. 2025 Aug;25(8):495-508. (IF 3.6)
19. Straub BK, Müller L, Duret DS, **Tóth M**, Mittler J, **Schirmacher P**. Morphomolekulare Subtypisierung hepatozellulärer Adenome [Morphomolecular subtyping of hepatocellular adenoma]. Pathologie (Heidelb). 2025 Nov;46(6):338-346. German. (IF 0.7)
20. Till A*, Siddiqui RA*, **Altbürger C***, Schwarz R, Huebner T, Wolf J, Andres D, Anker A, Aretz S, Haack TB, Berlage T, Beule D, Boerries M, Buchhalter I, Bussmann J, Engel C, Friedrichs J, Fröhling S, Haenisch B, Hahne A, Hübschmann D, von Kessel F, Klatt R, Kreutzfeldt S, Kron A, Krude H, Lübbe A, Lührig U, Malek N, Mertes C, Möller Y, Mundlos C, Nöthen MM, Ossowski S, Pötschke L, Rasokat A, Riess O, Schade S, **Schirmacher P**, Schmutzler R, Scholl C, Semler SC, Spielmann M, Stegle O, **Stenzinger A**, Straßburger J, Schröck E, Krawczak M, Kohlbacher O. Germany's national genomDE strategy. Nat Med. 2025 Dec;31(12):3981-3984. (IF 50.0)
21. Torlakovic EE, Al Dieri R, Badrick T, Chen ZE, Cheung CC, Deans Z, Dodson A, Fenizia F, Kijima H, Maas J, Martinez A, Nielsen S, Patton S, Rouleau E, **Schirmacher P**, Shet T, Stockley T, Normanno N. Indirect clinical validation for predictive biomarkers in oncology: International Quality Network for Pathology (IQN Path) Position Paper. Virchows Arch. 2025 Sep;487(3):565-572. (IF 3.1)
22. Vogeser M, Brüggemann M, Sack U, **Stenzinger A**, Schliephake H; Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e.V.. Patient safety through quality assurance in in-vitro diagnostics - webinar 2024 of the Ad-hoc Commission on In-vitro Diagnostics of the Association of the Scientific Medical Societies in Germany (AWMF). Ger Med Sci. 2025 Jul 11;23:Doc05. (IF n/a)
23. Welcker K, Jonigk D, Kropf-Sanchen C, Tufman A, Draube A, **Stenzinger A,** Zaatar M, Thomas M. Neoadjuvante Therapie des resektablen, nicht-kleinzelligen Lungenkarzinoms [Neoadjuvant therapy for resectable non-small cell lung cancer]. Pneumologie. 2025 Jan;79(1):16-24. German. (IF 1.7)

## Book Chapters

**Longerich, T**. (2025). Kapitel 5: Histologische Diagnostik von Fibrose und Zirrhose. In: Bruns,T., Bettinger, D., Trebicka, J. (eds): Komplikationen der Leberzirrhose- Prävention, Diagnostik und Therapie, S.67-80. Springer, Berlin, Heidelberg. ISBN 978-3-662-70166-9